Legal Representation
Attorney
Marilyn F. Kelly
USPTO Deadlines
Next Deadline
179 days remaining
Statement of Use Due - Extension 3 Granted
Due Date
February 13, 2026
Extension Available
Until February 13, 2025
Application History
27 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Jul 31, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Jul 30, 2025 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
Jul 30, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Jul 30, 2025 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
Mar 4, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Jan 27, 2025 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
Jan 27, 2025 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
Jan 27, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Jul 25, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Jul 25, 2024 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
Jul 25, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
Jul 25, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Feb 13, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
Dec 19, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
Dec 19, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Nov 29, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
Nov 9, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Nov 8, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Nov 7, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Nov 7, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
Aug 11, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
Aug 11, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
Aug 11, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Aug 11, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Aug 2, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
Aug 1, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Jul 3, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use
Classification
International Classes
005